Investing.com - Leerink Partners将 Amicus Therapeutics (NASDAQ:FOLD) 的评级从"优于大盘"下调至"与大盘持平",并将目标价从17.00美元下调至14.50美元,此举是在 BioMarin 宣布收购后做出的。目前Amicus股价为14.25美元,接近其52周高点14.36美元,过去六个月内股价已飙升140.3%。根据 ...
Amicus Therapeutics (FOLD) has been drawing fresh attention after a strong recent share move, with the stock up about 46% over the past month and roughly 72% in the past 3 months. See our latest ...
If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value right now, this article walks through the key signals that matter for long term investors. The stock has ...
2025 年 7 月 25 日，华宇元典于公司成立9周年纪念日当天下午，在东升科技园公司现场举办了“华宇元典AI开放日”活动。现场汇聚法律界同仁、行业伙伴，活动全程进行了线上直播，线上线下的伙伴们一同回顾了元典九载发展历程，探讨AI与法律的深度融合，并 ...
Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision ...
The BioMarin Pharmaceutical Inc. acquisition of Amicus Therapeutics, Inc. will likely be beneficial and accretive for both ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈